Drug intelligence / Profile preview

carbon-11 cholylsarcosine

Development stage
Phase 1
Lead developer
Aarhus University
Modality
Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Carbon-11 cholylsarcosine is a radiolabeled synthetic bile acid analog developed for use as a positron emission tomography (PET) tracer. It is composed of cholic acid conjugated with sarcosine (N-methylglycine), where the methyl group is labeled with the positron-emitting isotope carbon-11. Unlike natural bile acid conjugates like glycocholate or taurocholate, cholylsarcosine is resistant to deconjugation and dehydroxylation by intestinal bacteria, allowing it to remain intact throughout the enterohepatic circulation. This stability makes it a highly effective probe for the non-invasive quantification of hepatic bile acid uptake, biliary secretion, and intestinal reabsorption. It is primarily utilized in clinical research to investigate hepatobiliary function, cholestatic liver diseases, and bile acid malabsorption syndromes.

Other names
carbon-11 labeled cholylsarcosinecarbon11 labeled cholylsarcosinecarbon 11 labeled cholylsarcosine11C-labeled cholylsarcosine
02

Targets

ABCB11 (Bile salt export pump)

Beyond the preview

Go deeper on carbon-11 cholylsarcosine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on carbon-11 cholylsarcosine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call